Passage Bio Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Passage Bio Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- PASG
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001787297
Board of directors
-
Athena Countouriotis · DirectorSince 2023
-
Derrell Porter · DirectorSince 2023
-
Dolan Sondhi · DirectorSince 2023
-
Maxine Gowen · DirectorSince 2023
-
Michael E. Kamarck · DirectorSince 2023
-
Sandip Kapadia · DirectorSince 2023
-
Saqib Islam · DirectorSince 2023
-
Thomas Richard Kassberg · DirectorSince 2024
-
Thomas Woiwode · DirectorSince 2023
-
William Chou · Director · PRESIDENT AND CEOSince 2023
Chief executives
William Chou
· President and CEO
Dates unknown
Board connections
5 of this board's directors also sit on 6 other boards.
- via Saqib Islam
- via Maxine Gowen
- via Derrell Porter
- via Athena Countouriotis
- via Athena Countouriotis
- via Michael E. Kamarck
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 27, 2024 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +373,645 | $0.65 | $242,869 |
| Dec 20, 2024 | OrbiMed Capital GP VII LLC 10% owner | Open-market sale | −230,321 | $0.60 | $138,193 |
| Dec 11, 2024 | ORBIMED ADVISORS LLC 10% owner | Open-market sale | −80 | $0.80 | $64 |
| Dec 10, 2024 | ORBIMED ADVISORS LLC 10% owner | Open-market sale | −8,015 | $0.80 | $6,412 |
| Dec 9, 2024 | ORBIMED ADVISORS LLC 10% owner | Open-market sale | −54,181 | $0.84 | $45,512 |
| Dec 6, 2024 | OrbiMed Capital GP VII LLC 10% owner | Open-market sale | −20,903 | $0.82 | $17,140 |
| Dec 4, 2024 | OrbiMed Capital GP VII LLC 10% owner | Open-market sale | −76,200 | $0.79 | $60,198 |
| Nov 27, 2024 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +29,300 | $0.67 | $19,631 |
| Nov 26, 2024 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +167,055 | $0.71 | $118,609 |
| Nov 25, 2024 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +259,998 | $0.56 | $145,599 |
| Sep 19, 2024 | ORBIMED ADVISORS LLC 10% owner | Open-market sale | −39,300 | $0.71 | $27,903 |
| Sep 18, 2024 | OrbiMed Capital GP VII LLC 10% owner | Open-market sale | −25,631 | $0.73 | $18,711 |
| Sep 17, 2024 | OrbiMed Capital GP VII LLC 10% owner | Open-market sale | −111,400 | $0.73 | $81,322 |
| Sep 16, 2024 | OrbiMed Capital GP VII LLC 10% owner | Open-market sale | −63,100 | $0.74 | $46,694 |
| Feb 13, 2024 | Borthwick Kathleen Officer (SVP, INTERIM CFO) | Open-market sale | −1,470 | $0.97 | $1,426 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.